Status Epilepticus
79
18
18
38
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.9%
7 terminated out of 79 trials
84.4%
-2.1% vs benchmark
19%
15 trials in Phase 3/4
21%
8 of 38 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 38 completed trials
Clinical Trials (79)
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
Training Program to Improve EEG Competence
Patient-reported Outcome and Patient-reported Experience After Status Epilepticus
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
Simulation Trial of Telemedical Support for Paramedics
De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Recovery Trajectory for Coma and Disorders of Consciousness
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
EEG Monitoring for Refractory Status Epilepticus
Improving Status Epilepticus Treatment Times
Status Epilepticus in Men and Women: Clinical Presentation, Management, and Outcomes
Augmented Renal Clearance in Neurocritical Care
Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus
Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus
Point-of-care EEG in the Pediatric Emergency Department
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus